hrp0086fc5.3 | Management of Disorders of Insulin Secretion | ESPE2016

Glibentek, a New Suspension of Glibenclamide for Patients with Neonatal Diabetes, is as Effective and more Convenient than Crushed Tablets

Beltrand Jacques , Godot Cecile , Busiah Kanetee , Djerada Zoubir , Baron Sabine , Tallec Claire Le , Tessier Raphael , Ribault Virginie , Cartigny Maryse , Bruel Henri , Gozalo Claire , Treluyer Jean-Marc , Elie Caroline , Polak Michel

Background: Glibenclamide has proven to be efficient for patients with neonatal diabetes owing to potassium channel mutations. Anyway its pharmaceutical form is not suitable for young children or infants. The tablets dosage is too high for most infants and must be crushed and diluted before administration. We developed a suspension of glibenclamide (EMA Orphean drug designation january 2016) fitting recommendations of drug administration to allow a precise dosage and designed ...

hrp0095p1-162 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Complications of non-endocrine pituitary tumors in children, in the city of Oran

Faraoun Khadra , Chentli Farida , Zoubir Safia , Midoun Nori

Background: Non-endocrine pituitary tumors (NEPT) correspond to expansive processes, developing at the expense of non-endocrine pituitary lodge structures. Our objective is to evaluate their prevalence and their incidence rates in Oran, Algeria.Patients and Methods: This is a cross-sectional descriptive multicenter study in the town of Oran study. Data were collected prospectively from Avril 2014 to Mars 2015 and retrosp...

hrp0095p1-560 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Craniopharyngiomas in children: Hormonal profile and regional complications

Faraoun Khadra , Chentli Farida , Zoubir Safia , Midoun Nori

Background: The craniopharyngioma is a non-endocrine tumor, developed along the infundibulo-pituitary axis, from the third ventricle to sphenoid, histologically benign but locally invasive. It is a tumor with serious complications because of its location, its considerable potential for extension, its tendency to recur, and its adhesions to neighbouring structures. Our aim is to assess hormonal profile, neuro-ophthalmological and metabolic complications at the ...

hrp0089p3-p288 | Pituitary, Neuroendocrinology and Puberty P3 | ESPE2018

Bilateral Optic Nerve Hypoplasia Revealing Septo Optic Dysplasia or De Morsier Syndrome: A Case Report

Yamina Aribi , Meriem Bensaleh , Lila Brakni , Zoubir Sellal , Aicha Lachkhem , Samia Ouldkablia

Background: Septo-optic dysplasia (SOD) is a congenital affection characterized by classic triade: optic nerve hypoplasia, hypothalamic-pituitary endocrine deficits and mdline abnormalities of the brain. It is typically diagnosed in infancy and has a variable presentation.Case presentation: The patient is an 5 year old Algerian girl. At birth, bilateral congenital nystagmus and strabism was noted? Right blindness was suspected by parents at age of 2 year...

hrp0095p2-262 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Analyze of clinical, biological and therapeutic aspects of 46 XY DSD

Iabbassen Malek , Bensalah Meriem , Brahimi Hanane , Benabdellatif Katia , Sellal Zoubir , Zahaf Hamid , Mouloud Benaired Amine , Choutri Hichem , Khadidja Ouldkablia Samia

Background: Clinical spectrum of 46 XY DSD is characterized by a greatest diversity. Atypical sex development can occur through different steps of testicular differentiation. Etiologies of 46 XY DSD are termed gonadal dysgenesis, hormonal dysfunction and action. Its global incidence is unknown but the most common presentation, hypospadias, is understood to occur in 1 in 125 male births, and complete androgen insensitivity has an incidence of 1:20,000 people.</...

hrp0097p1-98 | GH and IGFs | ESPE2023

Evaluation of patients with growth hormone deficiency during the transition period

Bensalah Meriem , Iabbassen Malek , Haffaf Lounes , Bouchenna Amira , Lachkhem Aicha , Yahi Abdelkader , Sellal Zoubir , Medjaher Meriem , Khadidja Ouldkablia Samia

Introduction: The transition period between childhood and adulthood in patients with growth hormone deficiency is a vulnerable period during the follow-up. Different consensuses have established follow-up and reassessment protocols for this period in order to clarify whether GHD persists. The benefits of maintaining treatment during this period are widely documented on the metabolic, vascular, bone and in terms of quality of life and well-being.<p class="a...